Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.44) by 34.09 percent. This is a 81.39 percent increase over losses of $(3.17) per share from the same period last year.
DLocal’s Stellar Q2 Performance And New Co-CEO Appointment: Why Analyst Is Bullish On Future Prospects
Susquehanna analyst James E Friedman reiterated a Positive rating on DLocal Limited (NASDAQ: DLO),
